PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 63 filers reported holding PROQR THRAPEUTICS N V in Q1 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $6,354,000 | -88.7% | 7,019,610 | -0.1% | 0.13% | -83.9% |
Q4 2021 | $56,292,000 | +4.4% | 7,027,725 | +9.1% | 0.82% | +1.1% |
Q3 2021 | $53,929,000 | +24.2% | 6,443,113 | 0.0% | 0.81% | +24.1% |
Q2 2021 | $43,427,000 | +2.3% | 6,443,113 | +0.3% | 0.66% | -1.2% |
Q1 2021 | $42,463,000 | +101.8% | 6,424,078 | +28.2% | 0.66% | +87.8% |
Q4 2020 | $21,041,000 | -11.7% | 5,009,768 | +0.7% | 0.35% | -38.5% |
Q3 2020 | $23,822,000 | -20.1% | 4,973,174 | +1.4% | 0.57% | -31.6% |
Q2 2020 | $29,809,000 | +13.6% | 4,902,785 | +2.6% | 0.84% | -25.7% |
Q1 2020 | $26,237,000 | -44.6% | 4,779,135 | 0.0% | 1.13% | -36.8% |
Q4 2019 | $47,361,000 | +122.2% | 4,779,135 | +29.1% | 1.79% | +40.9% |
Q3 2019 | $21,317,000 | -37.1% | 3,700,833 | -0.6% | 1.27% | -29.9% |
Q2 2019 | $33,879,000 | -34.4% | 3,722,950 | 0.0% | 1.81% | -48.7% |
Q1 2019 | $51,637,000 | +630.2% | 3,722,950 | +730.8% | 3.52% | +435.7% |
Q4 2018 | $7,072,000 | -90.2% | 448,141 | -88.0% | 0.66% | -84.8% |
Q3 2018 | $72,358,000 | – | 3,739,406 | – | 4.33% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 1,237,400 | $5,197,000 | 1.55% |
Prosight Management, LP | 255,000 | $1,071,000 | 0.50% |
RTW INVESTMENTS, LP | 5,009,768 | $21,041,000 | 0.35% |
Kerrisdale Advisers, LLC | 453,182 | $1,903,000 | 0.15% |
Artal Group S.A. | 1,196,218 | $5,024,000 | 0.11% |
COWEN AND COMPANY, LLC | 285,696 | $1,200,000 | 0.11% |
Golden Green, Inc. | 16,999 | $71,000 | 0.07% |
APOGEM CAPITAL LLC | 15,855 | $67,000 | 0.04% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,550,062 | $19,110,000 | 0.04% |
ALTRINSIC GLOBAL ADVISORS LLC | 241,360 | $1,014,000 | 0.03% |